18th week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220133621 | Cosmetic Composition - Non-therapeutic methods of improving an individual's mood and of treating sensitive skin are provided. | 2022-05-05 |
20220133622 | INSTANT EFFECT EYE CREAM - The present disclosure provides methods and compositions for treating skin around an eye area of a face. The method entails applying a composition that includes a unique combination of rheology-modifying agents that efficiently maintains active agents in suspension. The composition exhibits pleasing skin feel, softens skin, and attracts and retains moisture while maintaining these desirable properties over time. | 2022-05-05 |
20220133623 | Antipsychotic Injectable Depot Composition - The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks. | 2022-05-05 |
20220133624 | METHOD FOR PRODUCING ORAL DISINTEGRATING FILM COMPRISING POORLY SOLUBLE DRUG - The present disclosure relates to a method for producing an oral disintegrating film by a 3D printing technology which utilizes a hot-melt pneumatic extrusion method, and when a mixture including a poorly soluble drug, a film-forming polymer, and a plasticizer confirmed in the present disclosure was produced as an oral disintegrating film using the production method of the present disclosure, it was confirmed that the production method was simplified because the production process became one process, the production costs were decreased, and a poorly soluble drug having a problem in that bioavailability deteriorated due to an existing low solubility could obtain excellent solubility. | 2022-05-05 |
20220133625 | METHOD FOR ELIMINATING SPECIFIC PATHOGENIC MICROORGANISMS IN THE BODY - The method for eliminating microorganisms, allows to selectively neutralize pathogens. The method includes a first step which includes measuring the frequencies of pathogens within a human body which are at high population present, resulting in further illnesses or symptoms. The different sized pathogens are then applied a resonant frequency band to pre-damage/crack/weaken the hulls of the microorganisms evenly. The method further includes a second step rupturing the damaged hulls of the pathogens or oxidation of the ARN/ADN in case of a virus with a safe dose of an external oxidation product together with internal produced eNOS-expression (ROS/RNS). The external product may include chlorine dioxide in a watery solution of 0.75 ppm, vitamins, minerals and amino acids to start eNOS-expression. The method further includes a third step to deliberately terminating the activated oxidation processes. A fourth step strengthens the immune system by filling depleted levels of vitamins, minerals and amino acids. | 2022-05-05 |
20220133626 | TOPICAL COMPOSITIONS AND METHODS OF USE THEREOF - The invention is directed to a topical composition comprising one or more topical active ingredients, one or more nonionic surfactants, one or more viscosity enhancers, polyethylene glycol and menthol. The invention is further directed to a method of reducing or eliminating pain comprising applying a composition of the present invention to a subject in need thereof. | 2022-05-05 |
20220133627 | Stable Therapeutic Formulations - Compositions of and methods for formulating and delivering biologically active agent formulations having enhanced physical stability, and wherein deterioration from the presence of oxygen and/or water is minimized and/or controlled, to yield a stable formulation. The compositions of and methods for formulating and delivering biologically active agents of the present invention further facilitate their incorporation into a biocompatible coating which can be employed to coat a stratum-corneum piercing microprojection, or a plurality of stratum-corneum piercing microprojections of a delivery device, for delivery of the biocompatible coating through the skin of a subject, thus providing an effective means of delivering the biologically active agents. | 2022-05-05 |
20220133628 | LUBRICANT FORMULATIONS - A composition for lubricant formulations is disclosed. The composition may include hypochlorite, dimethicone, and an emulsifier for improvement of lubricity. Methods of making and using the lubricant formulations are also disclosed. | 2022-05-05 |
20220133629 | FORMULATIONS FOR TREATMENT OF DRY EYE DISEASE - The present invention provides a reproxalap ophthalmic solution, and methods of using the same for treating dry eye disease. | 2022-05-05 |
20220133630 | PREPARATION METHOD OF SUSTAINED-RELEASE MICROPARTICLES - The whole preparation process of the sustained-release microparticles is at normal or low temperature, which is highly advantageous for the preparation of a polymer-based composition from a high-temperature-sensitive drug, particularly a protein, nucleic acid and peptide drug, and the bioactivity of the active substance can be maintained to the greatest extent throughout the process compared to the disclosed technology; at the same time, the prepared sustained-release microparticles have an excellent sustained-release effect close to zero order, and the drug concentration is stabilized during the release, which overcomes the defects that the microparticles obtained by the conventional S/O/W process of pre-preparing the drug microparticles have no drug release in the earlier stage and a rapid release of the drug in the later stage; and in addition, the sustained-release microparticles have higher drug loading rate and drug encapsulation rate. | 2022-05-05 |
20220133631 | PROCESS OF PREPARING ICE-BASED LIPID NANOPARTICLES - The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing an mRNA solution containing low citrate concentration and a lipid solution at an ambient temperature. Thus, the present invention provides an effective, reliable, energy-saving and cost-effective method of encapsulating mRNA into lipid nanoparticles. | 2022-05-05 |
20220133632 | PLGA MICROPARTICLES, A SUSTAINED RELEASE FORMULATION THEREOF AND A PRODUCTION METHOD THEREOF - The present application provides approximately spherical lactic acid-glycolic acid copolymer (PLGA) microparticles comprising a biologically active substance, wherein an average volume-based particle diameter of the PLGA microparticles is 1 μm or more and 150 μm or less, and a Reactive Span Factor (R.S.F.) of the PLGA microparticles is satisfied with formula (1): 0.1<(R.S.F.)≤1.7 formula (1), wherein an R.S.F. means (D90−D10)/D50; D90 is a particle diameter (μm) corresponding to the cumulative 90% by volume of the cumulative particle diameter distribution from the small particle side; D50 is a particle diameter (μm) corresponding to the cumulative 50% by volume of the cumulative particle diameter distribution from the small particle side; and D10 is a particle diameter (μm) corresponding to the cumulative 10% by volume of the cumulative particle diameter distribution from the small particle side; and an efficient production method thereof. The present invention provides the approximately spherical PLGA microparticles having an average volume-based particle diameter of 1 μm or more and 150 μm or less wherein there are few coarse particles or ultrafine particles without a classification step, and the particle diameter distribution is sharp around the target particle diameter. | 2022-05-05 |
20220133633 | PHARMACEUTICAL TACI-FC FUSION PROTEIN FORMULATION - Disclosed is a pharmaceutical formulation containing a mixture of a non-reducing sugar, a TACI-Fc fusion protein and at least one amino acid. The pharmaceutical formulation has the characteristics of reducing particulate matter, reducing aggregate formation, improving the stability, improving the appearance of a freeze-dried powder, etc. | 2022-05-05 |
20220133634 | SUSTAINED RELEASE SOLID DOSAGE FORMS FOR MODULATING THE COLONIC MICROBIOME - Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease. | 2022-05-05 |
20220133635 | Delayed Release Methylphenidate Compositions - The present disclosure provides programmable osmotic-controlled oral compositions providing delayed extended release of a therapeutically acceptable amount of methylphenidate hydrochloride. The programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, and volume of gastric fluid. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm that matches the circadian rhythm of an individual being treated to optimize therapeutic outcome and minimize side effects. | 2022-05-05 |
20220133636 | CATIONIC LIPIDS CONTAINING SILICON - Certain embodiments of the invention provide a cationic lipid of formula (I): wherein R | 2022-05-05 |
20220133637 | COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS - The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid. | 2022-05-05 |
20220133638 | METHOD FOR PRODUCING NANOPARTICLES - The present invention describes a method for producing nanoparticles, wherein the nanoparticles contain or consist of hydroxypropyl methylcellulose acetate succinate (HPMCAS), and wherein i) HPMCAS is dissolved in an organic solvent in order to obtain an organic solution and ii) the organic solution is mixed with water to precipitate the nanoparticles in order to obtain precipitated nanoparticles and a mixed liquid phase as well as nanoparticles obtained by that method. | 2022-05-05 |
20220133639 | SURFACE FUNCTIONALIZED, HOST-GUEST POLYMER NANO-ASSEMBLIES AND METHODS THEREOF - The invention generally relates to polymer-based nano-structures. More particularly, the invention relates to novel, surface-functionalized, guest-host polymer nano-assemblies and nano-delivery vehicles useful in diverse fields including drug delivery, diagnostics and specialty materials. The nano-assemblies and nano-delivery vehicles of the invention are afforded via simplify and reliable approaches. | 2022-05-05 |
20220133640 | COMPOSITION AND METHODS OF TREATMENT - The present invention relates nanoparticles formed of a polymer and an antifungal agent, wherein the polymer is selected from the group consisting of linear or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogues or derivatives thereof, or mixtures thereof. The nanoparticles are particularly suited for the treatment of fungal nail or skin infections. | 2022-05-05 |
20220133641 | TOPICAL FILM-FORMING SPRAY - A polymeric bio-adhesive film forming topical spray formulation providing a modified, pulsatile (e.g., biphasic) release of the active agent(s) once the solvent evaporates and the film sets, e.g., on human skin is disclosed. In certain embodiments, the active agent is bupivacaine hydrochloride. | 2022-05-05 |
20220133642 | TOPICAL FILM-FORMING SPRAY - A polymeric bio-adhesive film forming topical spray formulation providing a modified, pulsatile (e.g., biphasic) release of the active agent(s) once the solvent evaporates and the film sets, e.g., on human skin is disclosed. In certain embodiments, the active agent is bupivacaine hydrochloride. | 2022-05-05 |
20220133643 | ADHESIVE PATCH - The present invention provides a patch comprising an adhesive layer on a backing, wherein the adhesive layer contains a adhesive base, a skin irritant drug or a pharmaceutically acceptable salt thereof, and diflucortolone valerate, and the content of the diflucortolone valerate is 0.0009 to 0.08% by mass based on the total mass of the adhesive layer. | 2022-05-05 |
20220133644 | MICROCELL SYSTEMS FOR DELIVERING BENEFIT AGENTS - A benefit agent delivery system whereby benefit agents can be released over a period of time and/or a variety of different benefit agents can be delivered from the same system and/or different concentrations of benefit agents can be delivered from the same system. The benefit agent delivery system includes a plurality of microcells, wherein the microcells are filled with a formulation comprising a benefit agent and an organic solvent. The microcells include an opening, and the opening is spanned by a porous diffusion layer. Different microcells may be loaded with different benefit agents, thereby providing a mechanism to deliver different, complimentary, or incompatible benefit agents. | 2022-05-05 |
20220133645 | MICROCELL SYSTEMS FOR DELIVERING HYDROPHILIC ACTIVE MOLECULES - A hydrophilic active molecule delivery system whereby active molecules can be released on demand and/or a variety of different active molecules can be delivered from the same system and/or different concentrations of active molecules can be delivered from the same system. The system may be used to deliver/release hydrophilic active molecules that are incompatible to each other. | 2022-05-05 |
20220133646 | SOLUBILIZATE WITH CURCUMIN AND AT LEAST ONE CANNABINOID AS A FURTHER ACTIVE SUBSTANCE - In order to make available the health-promoting and healing properties of curcumin and/or cannabinoids to the human organism, the invention provides a solubilizate consisting of or comprising curcumin in a content equal to or less than 10 wt. %, and at least one cannabinoid as at least one further active substance, as well as at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or at least one sucrose ester of edible fatty acids, and a solubilizate comprising, in particular consisting of at least one cannabinoid in a content of less than or equal to 10 wt. % and at least one emulsifier having an HLB value in a range of less than 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or at least one sucrose ester of edible fatty acids. | 2022-05-05 |
20220133647 | LIQUID GUAIFENESIN COMPOSITIONS WITH STABLE EXTENDED RELEASE PROFILES - The present disclosure provides drug-containing sustained-release particles that have minimal loss of the drug from the particle when the particle is formulated as a suspension in a liquid phase that is saturated by the drug. | 2022-05-05 |
20220133648 | TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES - The present invention relates to methods of treating Leigh Syndrome and Leigh-like Syndrome with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease. | 2022-05-05 |
20220133649 | AFFINITY MEDICANT CONJUGATE - In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The medicant moiety can be a toxin including an acylfulvene or a drug moiety. The affinity moiety can be an antibody, a binding protein, a steroid, a lipid, a growth factor, a protein, a peptide or non peptidic. The affinity moiety can be covalently bound to the medicant via a linker. Novel linkers that can be directed to cysteine, arginine or lysine residues based on solution pH allow greater flexibility in preserving and/or generating specific epitopes in the AMC. | 2022-05-05 |
20220133650 | COMBINATION THERAPY FOR TREATMENT OF BRAIN DISORDERS - A combination therapy, comprising a pharmaceutical composition of an N-Methyl D-Aspartate receptor (NMDA) receptor blocker and a Transforming Growth Factor beta (TGF-β) receptor antagonist, for treatment of brain diseases associated with BBB dysfunction. | 2022-05-05 |
20220133651 | TREATMENT OF PITT-HOPKINS SYNDROME - The present invention relates to amitriptyline or a pharmaceutically acceptable sale thereof, for use in the treatment of Pitt-Hopkins syndrome. | 2022-05-05 |
20220133652 | A FORMULATION FOR IMPROVING SEIZURE CONTROL - Described herein is a method of improving seizure control in a patient experiencing uncontrolled seizures persisting 10 minutes or more, comprising administering fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, at a dose of from 0.2 to 1.2 m/kg/day for a period of about 12 hours to about 7 days to a patient having been put into a therapeutic, medically-induced coma via a general anesthetic; and after about 12 hours to about 7 days, weaning the patient from the general anesthetic and assessing whether the seizure control has improved as compared to a pre-treatment time point. The patient experiencing seizures may have epilepsy or epileptic encephalopathy that has led to established status epilepticus (SE), refractory status epilepticus (RSE) or super-refractory status epilepticus (SRSE). | 2022-05-05 |
20220133653 | METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISORDERS: AMBROXOL AS TREATMENT AGENT FOR MUCOPOLYSACCHARIDOSES III (SANFILIPPO SYNDROME) - Methods for treating MPS III diseases are disclosed. The methods involve administering a therapeutically effective amount of a composition comprising ambroxol to a subject with the disease. Also disclosed are pharmaceuticals suitable for treating MPS III diseases. | 2022-05-05 |
20220133654 | SUBLINGUAL EPINEPHRINE TABLETS - The present disclosure provides sublingual epinephrine tablets and methods of treating anaphylaxis, methods for concomitant therapy during a cardiac event, treating hypoglycemia, and prophylaxis for immunotherapy, using sublingual epinephrine tablets. | 2022-05-05 |
20220133655 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2022-05-05 |
20220133656 | METHODS OF TREATING TRIGEMINAL NERVE PAIN - Provided are methods for treating trigeminal nerve pain in a subject in need thereof. The method may include administering to the subject by perineural injection of the trigeminal nerve a therapeutically effective amount of a composition comprising an alpha-2 adrenergic agonist, such as guanfacine. The composition may further comprise lidocaine. | 2022-05-05 |
20220133657 | COMPOUNDS FOR PREVENTION AND TREATMENT OF OBESITY AND RELATED DISORDERS - Presented herein, in certain aspects, are methods of treating or preventing obesity, assisting or inducing weight loss, suppressing apatite, or inhibiting weight gain in a subject by administering a compound of the invention to a subject. | 2022-05-05 |
20220133658 | TOPICAL ANALGESIC COMPOSITIONS AND METHODS OF USE - The present invention is directed to topical skin composition comprising one or more active ingredients and one or more permeation enhancers. The present invention is further directed to a method of reducing or eliminating pain. | 2022-05-05 |
20220133659 | THERAPEUTIC AGENT FOR CORNEAL DISEASES - The present invention relates to a novel means for treating corneal diseases. The present invention provides a therapeutic agent for corneal diseases, containing a compound represented by the following formula (I): | 2022-05-05 |
20220133660 | METHODS OF TREATMENT USING SUSTAINED RELEASE SOTALOL FORMULATIONS - Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In some examples, sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period, e.g., at least about 24 hours. | 2022-05-05 |
20220133661 | PHARMACEUTICAL COMPOSITION EXHIBITING ANTI-TUMOR ACTIVITY, METHOD FOR TREATING PATIENT SUFFERING FROM CANCER AND METHOD FOR INHIBITING TUMOR GROWTH - A pharmaceutical composition exhibiting anti-tumor activity is provided. The pharmaceutical composition comprises para-toluenesulfonamide (PTS) and a pharmaceutically acceptable carrier. The pharmaceutical composition is used for treating squamous-cell carcinoma. The present invention further provides a method for treating a patient suffering from cancer and a method for inhibiting tumor growth. | 2022-05-05 |
20220133662 | ORAL DRUG, ADJUVANT CANCER THERAPY, AND PET THERAPEUTIC DIET - An oral drug includes powdered poly (R)-3-β-hydroxybutyric acid having a weight-average molecular weight of 10,000 to 700,000. The oral drug includes the powdered poly (R)-3-β-hydroxybutyric acid having (a) a purity of 70% or more and (b) a weight-average molecular weight of 10,000 to 590,000. The oral drug includes the powdered poly (R)-3-β-hydroxybutyric acid having (a) a purity of 90% or more and (b) a weight-average molecular weight of 10,000 to 590,000. An oral drug for increasing a ketone body concentration in blood that includes powdered poly (R)-3-β-hydroxybutyric acid having a weight-average molecular weight of 10,000 to 700,000. According to the present disclosure, an increased ketone body concentration in the blood is sustained for a longer period of time. | 2022-05-05 |
20220133663 | METHOD OF MANUFACTURING MECHANORECEPTION STIMULATION FABRIC - A method for manufacturing a mechanoreception fabric for incorporation into a garment or item of apparel sets a liquid substrate to a fabric weave to produce a plurality of protuberances in graticulate array and spaced apart across a surface of the fabric. The plurality of protuberances includes pyramidal nodes, each independent and separate from other nodes, not less than 1 mm apart at the base and not more than 5 mm apart at each apex and 1.5 mm in height. Because the nodes are separated and not in contact with each other, the fabric produced is still stretchable and wearable when incorporated into an item of apparel despite the nodes having a hardness of between Shore A 60 and 80. | 2022-05-05 |
20220133664 | COMPOSITIONS INCLUDING CINNAMIC ACID AND METHODS OF USE THEREOF - This disclosure relates to pharmaceutical compositions useful for inhibiting the progression of a neurodegenerative disorder or glycine encephalopathy. The pharmaceutical compositions may include cinnamic acid. The pharmaceutical compositions and formulations may be orally administered to the patient. | 2022-05-05 |
20220133665 | COMPOSITION FOR INDUCING PILI FORMATION IN BACTERIUM OF GENUS BIFIDOBACTERIUM - The object is to provide a method for inducing pili formation in bacterium of genus | 2022-05-05 |
20220133666 | METHODS OF TREATMENT OF CHOLESTATIC DISEASES - The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC. | 2022-05-05 |
20220133667 | Method of Making a Magnesium Salt of an Alpha Keto Acid of Leucine, Isoleucine, and Valine - A method of making a magnesium salt of an alpha keto acid of the amino acid comprising valine, leucine, and/or isoleucine: 1) combining ingredients comprising: a calcium salt of an amino acid valine, leucine, or isoleucine; water; hydrochloric acid; and methyl tert-butyl ether; 2) stirring for about thirty minutes; 3) allowing the composition to settle into two layers, and collecting the top organic layer, and adding water and magnesium carbonate to the top organic layer; 4) heating the composition for one hour to 60-65° Celsius; 5) removing the solvent, cooling, and adding methyl-tert-butyl ether; 6) stirring the composition for one hour at 25-30° Celsius; 7) filtering, washing, drying under vacuum, and storing the composition as a powder; and 8) wherein the powder is a safe consumable low nitrogen product orally administered within a food, a beverage, or a tablet to treat kidney disease. | 2022-05-05 |
20220133668 | ISOTOPICALLY MODIFIED COMPONENTS AND THERAPEUTIC USES THEREOF - Methods are provided of identifying a subject having impaired aldehyde dehydrogenase activity; and administering to the subject a compound comprising an isotopicaliy-modified polyunsaturated fatty acid, an isotopicaliy-modified polyunsaturated fatty acid ester, an isotopicaliy-modified polyunsaturated fatty acid thioester, an isotopicaliy-modified polyunsaturated fatty acid amide, a polyunsaturated fatty acid mimetic, or an isotopicaliy-modified polyunsaturated fatty acid pro-drug, the compound having an isotopic modification that reduces oxidation of the compound, thereby reducing production in the subject of substrate for aldehyde dehydrogenase. Some aspects provide coadministering an isotopicaliy-modified polyunsaturated fatty acid and an oxylipin. | 2022-05-05 |
20220133669 | PHARMACEUTICAL COMPOSITIONS COMPRISING 15-HETRE AND METHODS OF USE THEREOF - Provided herein are pharmaceutical compositions comprising 15-HETrE and methods of using the same to treat a variety of conditions and disorders. | 2022-05-05 |
20220133670 | NUTRACEUTICAL FORMULATION FOR UNBLOCKING RECEPTORS - A nutraceutical formulation used to unblock receptors is disclosed herein. The nutraceutical formulation used to therapeutically treat humans includes arachidonic acid, docosahexaenoic acid (DHA), echinacea, kaempferol, coffee fruit, and probiotics. | 2022-05-05 |
20220133671 | ANTI-FIBROTIC NEU3 INHIBITOR COMPOUNDS AND METHODS OF USE - The present disclosure relates to methods of preventing or inhibiting fibrosis using small molecule sialidase inhibitors. The present disclosure also relates to methods treating obesity, liver inflammation, steatosis, and cancer. These methods can involve administering the compounds to a patent at risk of developing fibrosis inflammation, obesity, steatosis, or cancer, in a manner that inhibits NEU3. | 2022-05-05 |
20220133672 | NOTCH INHIBITORS FOR THE TREATMENT OF VASCULAR MALFORMATIONS - The present disclosure provides a method to treat or ameliorate vascular malformations, developmental abnormalities of one or more types of blood or lymphatic vessels. These are rare disorders with life-long risk of high morbidity including cosmetic concerns, pain, infection, pulmonary emboli, bleeding and even death. Treatment is difficult, and there is growing interest in improved therapies. The disclosure provides specific compounds that are inhibitors of Notch receptor signaling. In some embodiments, the compounds disclosed are gamma secretase inhibitors (GSIs). | 2022-05-05 |
20220133673 | KETONE BODY ESTERS OF S-BETA-HYDROXYBUTYRATE AND/OR S-1,3-BUTANEDIOL FOR MODIFYING METABOLIC FUNCTION - Compositions and methods for producing elevated blood levels of ketone bodies and modifying metabolic function in a mammal. Compositions include at least one ester of S-beta-hydroxybutyrate and/or a mono- or di-ester of S-1,3-butanediol and at least one ketone body component. The ketone body component includes beta-hydroxybutyrate, acetoacetate, or both. The beta-hydroxybutyrate is R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, or both. When the ketone body component is S-beta-hydroxybutyrate, the 1,3-butanediol is R-1,3-butanediol, S-1,3-butanediol, or both. Compositions may comprise a keto stack of multiple forms of ketone bodies. | 2022-05-05 |
20220133674 | ORALLY INGESTED COMPOSITION FOR IMPROVING SLEEP - The present invention addresses the problem of providing a novel orally ingested composition that contains a substance which is not conventionally known as an active component of a composition for improving sleep, and particularly, that can be easily taken orally and can improve sleep safely and easily. The present invention pertains to an orally ingested composition, particularly a food composition, for improving sleep and containing a choline ester as an active component In the present invention, the choline ester may be derived from an edible plant such as the fruit of the species | 2022-05-05 |
20220133675 | PHORBOL ESTER COMPOSITIONS AND METHODS OF USE FOR TREATING OR REDUCING THE DURATION OF CYTOPENIA - Methods and compositions containing a phorbol ester or a derivative of a phorbol ester in combination with G-CSF or in combination with EPO, are provided for the treatment of cytopenia in mammalian subjects. The compositions and methods also reduce the duration of cytopenia such as neutropenia, thrombocytopenia, and/or anemia. | 2022-05-05 |
20220133676 | CANNABINOIDS COMPOSITIONS WITH POLYUNSATURATED FATTY ACID MONOGLYCERIDES, METHODS AND USES THEREOF - There are provided compositions comprising at least one compound chosen from compound of formula (I), compound of formula (II), compound of formula (III) and compound of formula (IV): | 2022-05-05 |
20220133677 | TOPICAL COMPOSITION - Problem: To provide a topical composition having excellent permeability in the stratum corneum. Solution: A topical composition is prepared that comprises: (A) one antifungal agent or two or more antifungal agents selected from the group consisting of tolnaftate and pharmaceutically acceptable salts thereof; and (B) at least one compound selected from the group consisting of ester compounds of fatty acids having from 8 to 18 carbon atoms and dihydric alcohols having from 2 to 4 carbon atoms, lysine acyl glutamate, lysine diacyl glutamate, pharmaceutically acceptable salts of lysine acyl glutamate or lysine diacyl glutamate, diethylene glycol-based glycol ethers, cyclohexanedicarboxylic acid polyoxyethylene alkyl ethers, mannosylerythritol lipids, and sucrose fatty acid esters. | 2022-05-05 |
20220133678 | METHOD FOR TREATMENT OF ROSACEA - A regimen is described for the therapeutic treatment of rosacea. The regimen includes topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes from about 2.5% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The regimen achieves, in a group of such subjects, a primary measure of success of at least about 9%, at least about 25%, at least about 40%, or at least about 47%, after application of said pharmaceutical composition once daily for at least about 2 weeks, at least about 4 weeks, at least about 8 weeks, or at least about 12 weeks, respectively. | 2022-05-05 |
20220133679 | EFFLUX INHIBITOR COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME - The present invention relates to efflux inhibitor compositions and methods of using these agents for treating conditions where the activity of efflux transporter proteins (e.g., Breast Cancer Resistance Protein (BCRP) and P-Glycoprotein (P-GP)) inhibit effective delivery of a therapeutic agent to a target tissue (e.g., brain, spinal cord, nerves, cerebrospinal fluid, testis, eyeballs, retina, inner ear, placenta, mammary gland, liver, biliary tract, kidney, intestines, lung, adrenal cortex, endometrium, hematopoietic cells, and/or stem cells). | 2022-05-05 |
20220133680 | Compositions of Azadirachta Indica and Methods of Treating Cancer - The disclosure relates to compositions and methods of treating cancer in a subject. The method comprises administering to a patient in need of treatment an effective amount of supercritical CO | 2022-05-05 |
20220133681 | METHOD OF TREATMENT - Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS). | 2022-05-05 |
20220133682 | SOLUBILIZATE WITH CURCUMIN AND AT LEAST THE CANNABINOID THC AS A FURTHER ACTIVE SUBSTANCE - In order to make available the health-promoting and healing properties of curcumin and/or the cannabinoid THC to the human organism, the invention provides a solubilizate consisting of or comprising curcumin in a content equal to or less than 10 wt. %, and at least THC as at least one further active substance, as well as at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or at least one sucrose ester of edible fatty acids, and a solubilizate comprising, in particular consisting of at least one cannabinoid in a content of less than or equal to 10 wt. % and at least one emulsifier having an HLB value in a range of less than 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or at least one sucrose ester of edible fatty acids. | 2022-05-05 |
20220133683 | COMPOSITIONS FOR PREVENTING AND TREATING DIABETES - Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating diabetes, and methods for treating diabetes by topically or orally administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the patient in need of treatment. | 2022-05-05 |
20220133684 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR COUNTERING CHEMOTHERAPY INDUCED CARDIOTOXICITY - This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug). | 2022-05-05 |
20220133685 | FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS - Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits. | 2022-05-05 |
20220133686 | SOLID DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) COMPOSITIONS - The invention relates to a solid Δ | 2022-05-05 |
20220133687 | METHODS OF TREATING AND PREVENTING NEURODEGENERATIVE DISEASES WITH HGF ACTIVATING COMPOUNDS - A method for treating or preventing a neurodegenerative disease in a subject, the method comprising administering an HGF activating compound in a therapeutically effective amount to treat or prevent the neurodegenerative disease by activating HGF in the subject. The neurodegenerative disease may be, for example, Alzheimer's Disease, Parkinson's Disease, multiple sclerosis, dementia, or mild cognitive impairment. The methods may also be more generally directed to improving or enhancing cognitive ability, preventing or treating cognitive impairment, preventing or treating a neurodegenerative disease or condition, and/or preventing or treating a disease or condition associated with neuronal or synaptic loss according to the disclosed regimens. | 2022-05-05 |
20220133688 | MACROCYCLIC LACTONE ANTHELMINTICS AGAINST NEMATODES - The present invention relates to a milbemycin for use in control, treatment and/or prevention of infections with nematodes, preferably filariae, more preferably | 2022-05-05 |
20220133689 | TONGKAT ALI EXTRACT PRODUCTION PROCESSES AND USES THEREOF - Methods for isolating bioactive components from | 2022-05-05 |
20220133690 | Pharmaceutical Composition for Treatment of Bone-Related Disease - The present invention relates to a pharmaceutical composition for preventing or treating a bone-related disease; and the pharmaceutical composition is very effective in preventing or treating bone-related diseases in that it not only promotes differentiation of preosteoblast cells into osteoblasts to induce production of mineralized nodules, but also, at the same time, inhibits differentiation of bone marrow cells into osteoclasts and the function of osteoclasts so that bone homeostasis is effectively regulated. In addition, the present invention relates to a pharmaceutical composition for preventing or treating a menopausal disease, in particular, a menopausal bone disease; and the pharmaceutical composition is very effective in preventing or treating a menopausal bone-related disease in that it not only increases the volume of trabecular bone and promotes differentiation of preosteoblast cells into osteoblasts to induce production of mineralized nodules, but also, at the same time, inhibits differentiation of bone marrow cells into osteoclasts and the function of osteoclasts so that bone homeostasis is effectively regulated. | 2022-05-05 |
20220133691 | LASOFOXIFENE TREATMENT OF VVA AND OSTEOPOROSIS IN SURVIVORS OF BREAST CANCER AND OTHER MALIGNANCIES - The disclosure provides methods for treating vulvovaginal atrophy (VVA) and osteoporosis in breast cancer survivors and survivors of other malignancies with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. | 2022-05-05 |
20220133692 | SUPRAMOLECULAR PHOTOPROTECTION OF A PHOTOSENSITIZER - Disclosed herein are compositions comprising a water-soluble host-guest complex formed from a host receptor and a guest photosensitizer for the photoprotection of the photosensitizer. Also disclosed are methods of using the composition for generating reactive oxygen species, inhibiting the proliferation or killing of a cell, treating a subject with a cell proliferative disease or disorder. | 2022-05-05 |
20220133693 | THERAPEUTIC TREATMENT OF MICROSATELLITE UNSTABLE CANCERS - The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of microsatellite unstable cancers. In particular, the instant disclosure provides for identification of a cancer as exhibiting microsatellite instability (MSI) and/or impaired mismatch repair (MMR), and selection and/or administration of an inhibitor of the WRN helicase as a therapeutic agent for such a cancer and/or subject having or at risk of developing such a cancer. | 2022-05-05 |
20220133694 | PHARMACEUTICAL USE - The present invention relates to novel methods and pharmaceutical compositions for the treatment of heart failure in a patient. | 2022-05-05 |
20220133695 | SINGLE-DOSE PACKAGED CLOTRIMAZOLE LIQUID COMPOSITION - It relates to a single-dose packaging unit which is a blow-fill-seal (BFS) container which comprises a sterile pharmaceutical or veterinary liquid composition which is a solution, wherein a) the composition comprises a therapeutically effective amount of clotrimazole or a pharmaceutically or veterinary acceptable salt thereof, together with one or more pharmaceutically or veterinary acceptable excipients or carriers, and b) the container has a volume from 0.05 to 8 mL, with the condition that the water content of the composition is equal to or lower than 4% by weight with respect to the total composition weight. It also relates to a secondary packaging comprising one or more single-dose packaging units. | 2022-05-05 |
20220133696 | Ifetroban Treatment for Systemic Sclerosis - The present invention is directed to methods of treating, preventing, and/or ameliorating systemic sclerosis, by administration of a therapeutically effective amount of ifetroban or a pharmaceutically acceptable salt thereof. | 2022-05-05 |
20220133697 | INJECTABLE FORMULATIONS - The present disclosure relates to therapeutic compounds and formulations for treating, reducing the risk of, or for preventing a disease, disorder, or condition characterized by the presence of toxic aldehydes. | 2022-05-05 |
20220133698 | a-SYNUCLEIN AGGREGATE BINDING AGENT AND IMAGING METHOD - The present invention provides an α-synuclein aggregate binding agent that has high binding selectivity for an α-synuclein aggregate. | 2022-05-05 |
20220133699 | Antibacterial Compositions - Provided herein are methods of treating subjects having a bacterial infection by administering a peptide multimer and a carbapenem antibiotic. Also provided herein are methods of eliminating or inhibiting bacteria with a peptide multimer and a carbapenem antibiotic. Also provided herein are antibacterial compositions that include a peptide multimer and a carbapenem antibiotic. | 2022-05-05 |
20220133700 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS - Disclosed herein are pharmaceutical compositions for the treatment of neurologic disorders comprising an effective amount of one or more mTOR inhibitors and/or one or more BDNF inducers and optionally an effective amount of one or more thyroid hormones. Further disclosed herein are methods of treating or preventing neurologic disorders comprising administering an effective amount of a pharmaceutical composition comprising one or more mTOR inhibitors and/or one or more BDNF inducers and optionally an effective amount of one or more thyroid hormones. | 2022-05-05 |
20220133701 | METHODS OF TREATING PAIN - Methods of treating pain are provided. Accordingly, there is provided a method of treating nociceptive or neuropathic pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an agent which binds importin alpha3 or a polynucleotide encoding same and inhibits expression and/or activity of said importin α3. | 2022-05-05 |
20220133702 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS FOR TREATING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE - Described are methods of treating cystic kidney disease. Also disclosed are methods of reducing the size and/or number of cysts in autosomal dominant polycystic kidney disease. | 2022-05-05 |
20220133703 | HETEROARYL SUBSTITUTED BETA-HYDROXYETHYLAMINES FOR USE IN TREATING HYPERGLYCAEMIA - There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the ring containing Q | 2022-05-05 |
20220133704 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD - The disclosure relates to methods and compositions including p38 kinase inhibitors and agents that regulate expression of DUX4 and downstream genes including but not restricted to ZSCAN4, LEUTX, PRAMEF2, TRIM43, MBD3L2, KHDC1L, RFPL2, CCNA1, SLC34A2, TPRX1, PRAMEF20, TRIM49, PRAMEF4, PRAME6, PRAMEF15, or ZNF280A. Methods useful for treating a disease associated with abnormal DUX4 and downstream gene expression (e.g., Fascioscapulohumeral muscular dystrophy) are disclosed. | 2022-05-05 |
20220133705 | Composition for increasing skin thickness - A composition and method to increase skin thickness. The composition, preferably a topical lotion, may comprise skin thickening agents and a delivery agent, which in combination increases skin thickness, and may help reduce the possibility of injuries related to individuals suffering from thin or thinning skin, such as bruising or skin tears. | 2022-05-05 |
20220133706 | TARGETING NAD BIOSYNTHESIS IN THE TREATMENT OF CANCER - There are provided, inter alia, methods for treatment of cancer. The methods include means of identifying the NAD biosynthetic pathway on which depend cancer cells in a tumor, in a subject suffering from cancer. The methods further include administering to a subject in need a therapeutically effective amount of an inhibitor of the NMRK1 enzyme pathway to a tumor where the cancer cells are dependent of the NAD salvage pathway, allowing to lower the of dose FK866 administered to the subject. The methods also include administering to a subject in need a therapeutically effective amount of a bacterial inhibitor of NADSYN1 to a tumor where the cancer cells depend on the Preiss Handler pathway. | 2022-05-05 |
20220133707 | ARIMOCLOMOL FOR TREATING GLUCOCEREBROSIDASE ASSOCIATED DISORDERS - The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers and the acid addition salts thereof (arimoclomol), for use in a method of treating glucocerebrosidase associated disorders. | 2022-05-05 |
20220133708 | INHALABLE SUSTAINED THERAPEUTIC FORMULATIONS - The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties. | 2022-05-05 |
20220133709 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition is described. The composition comprises a drug component consisting of at least one indacaterol compound selected from indacaterol and indacaterol maleate, and at least one pharmaceutically acceptable salt of glycopyrrolate; and a propellant component at least 90 weight % of which is 1,1-difluoroethane (HFA-152a). | 2022-05-05 |
20220133710 | NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The present invention includes methods for treating a proliferative disorder comprising administering a therapeutically effective amount of crenolanib or a salt thereof in combination with pharmaceutical agent targeting apoptosis pathway proteins wherein the crenolanib and other agent are provided at least one of sequentially or concomitantly in a subject for use in the treatment of the proliferative disease, wherein the subject is a human subject. | 2022-05-05 |
20220133711 | CAMPTOTHECIN DERIVATIVES - Disclosed herein are novel cytotoxic compounds, and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this disclosure relates to novel camptothecin derivatives thereof, intermediates thereof, conjugates thereof, and pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular as anti-proliferative agents (anticancer agents). | 2022-05-05 |
20220133712 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES - The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection. | 2022-05-05 |
20220133713 | SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE - Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity. | 2022-05-05 |
20220133714 | EXTRACELLULAR MATRIX MODULATING AGENT - The present invention provide an agent for modulating expression of extracellular matrix by corneal endothelial cells. The present invention pertains to an agent for modulating expression of extracellular matrix by corneal endothelial cells containing, 1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof. | 2022-05-05 |
20220133715 | METHODS OF TREATING VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIA - The present invention concerns novel methods of treatment for venetoclax-resistant acute myeloid leukemia, particularly in subjects with a low expression of TP53 protein or expression of TP53 protein associated with a mutation of the TP53 gene, the methods comprising administering to the subject in need thereof a therapeutically effective amount of a NTRK/ALK/ROS1 inhibitor, or a pharmaceutically acceptable salt thereof. | 2022-05-05 |
20220133716 | RORGAMMA MODULATORS AND USES THEREOF - The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases. | 2022-05-05 |
20220133717 | RABEXIMOD IN THE TREATMENT OF RHEUMATOID ARTHRITIS - The present invention relates to therapeutic uses of compositions comprising 9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo-[2,3-b]quinoxaline in the treatment of human subjects suffering from Rheumatoid Arthritis. | 2022-05-05 |
20220133718 | PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE - The invention relates to pharmaceutical compositions, comprising a solid dispersion extrudate comprising any of certain active compounds that modulate cellular survival pathways implicating certain protein kinases, as described, for the treatment of cancer, and processes for the preparation of such compositions. The invention also relates to methods of administering such pharmaceutical compositions to patients for the treatment of cancer. | 2022-05-05 |
20220133719 | Composition for Treating the Eye - The invention relates to a composition containing, as active ingredient, ectoine, hydroxyectoine and/or salts, esters or amides of these compounds for the treatment and/or prophylaxis of diseases of the eye that are associated with a disturbance of the tear film. The disease can be in particular a keratoconjunctivitis sicca. It has been found that, surprisingly, these compounds are capable of preventing a rupture in the outer lipid layer of the tear film, avoiding an undesirably rapid evaporation of the lacrimal fluid. | 2022-05-05 |
20220133720 | PHARMACEUTICAL COMPOSITION OF SINGLE DOSAGE FORM FOR TREATING OR PREVENTING HYPERTENSION AND HYPERLIPIDEMIA - A pharmaceutical composition of a single dosage form for treating hypertension and hyperlipidemia is provided. Compartments containing a drug are formulated in separate forms to solve problems related to the dissolution and absorption of the drug due to drug interaction, and a biologically equivalent preparation can be obtained compared with a conventional single preparation. | 2022-05-05 |